Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NABGEM study in locally unresectable pancreatic cancer
NL-OMON23547Suspended
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) and Pancreatic carcinoma (PC), sponsored by Amsterdam University Medical Center. Primary endpoint: Disease control rate. Started Sep 2017; status: suspended.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)Pancreatic carcinoma (PC)
Beyond the preview
Go deeper on NL-OMON23547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23547.